HK Stock Market Move | CSPC Pharma (01093) rose by more than 4% during the trading day. Simcere Glucagon-Like Peptide-1 Long-Acting Injection (SYH9017) has received FDA approval for clinical trials.

CSPC PHARMA (01093) rose more than 4% in midday trading, up 3.57% as of the submission of this article, at 7.25 Hong Kong dollars, with a turnover of 7.14 billion Hong Kong dollars. On the news front, CSPC PHARMA announced that its GLP-1 receptor agonist, semaglutide long-acting injection (SYH9017), developed by the group, has been approved by the U.S. Food and Drug Administration (FDA) for clinical trials in the United States. It is reported that this product is the group's first long-acting formulation for monthly dosing in the GLP-1 field. It is worth noting that the company has recently disclosed several important developments, achieving breakthroughs in innovative drug clinical research and development, new drug approvals for marketing, and international strategic cooperation. The company's HER2 bispecific antibody combination therapy Phase III clinical trial data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, and trastuzumab deruxtecan has been approved for gastric cancer indication, with a full upfront payment of $1.2 billion received from AstraZeneca.